Orchid's team and an early user recount the company’s first liveborn baby (“Jeffy”) and present validation: embryo WGS data matched cord blood 10 months later, supporting detection of de novo mutations and reported clinical metrics (sensitivity/specificity/accuracy/precision). A parent reported 21 eggs → 16 embryos screened across hundreds of monogenic genes and polygenic scores (example: breast cancer risk 14% vs 37%); Orchid is in ~35 IVF centers.